Fabry Disease Cardiomyopathy: from Genes to Clinical Manifestations

Author(s): Attila Bela Kertesz, Istvan Edes

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 13 , 2012

Become EABM
Become Reviewer


Fabry disease is an X chromosome linked disorder caused by the inherited deficiency of lysosomal enzyme - galactosidase A. The deficiency results in abnormal degradation of certain glycosphingolipids. Although the disease is known for more than hundred years and the underlying molecular basis is getting to be well defined, there are still a lot of unanswered questions regarding the different clinical presentations, available diagnostic procedures and therapeutic interventions. The scope of the article is to review the molecular basis of Fabry disease and summarize the available data about Fabry disease cardiomyopathy, highlight the controversies of current knowledge and evaluate future research directions.

Keywords: Cardiomyopathy, chaperone, enzyme replacement therapy, Fabry disease, glycosphingolipids, sphingolipidosis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Page: [2477 - 2484]
Pages: 8
DOI: 10.2174/1389201011208062477
Price: $65

Article Metrics

PDF: 11